The following clinical trials are currently offered in Germany in this group. More about Chronic Lymphocytic Leukemia (CLL)
30 matching trials
The CLL17 study directly compares therapies that are already well-established in the treatment of chronic lymphocytic leukemia (CLL).
18 years and older · First line · Phase III
Chronic lymphocytic leukemia (CLL) is a malignant disease of the white blood cells (B lymphocytes) that requires treatment when symptoms appear; effective treatment options are available. However, the disease may relapse or fail to respond adequately to treatment (refractory). The bispecific antibody mosunetuzumab could be a new treatment option. The aim of this study is to investigate the safety and efficacy of mosunetuzumab alone and in combination with the drug venetoclax (already approved). Patients aged 18 and older with CLL who have already received treatment are eligible to participate in this study.
18 years and older · Relapsed / refractory · Phase I
Zanubrutinib is an already approved drug that can be used to treat patients with Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), or follicular lymphoma (FL). Since some of these conditions are very rare, there is not yet sufficient information on the use of this medication in clinical practice. The ARIADNE study is investigating how the treatment affects patients’ quality of life, including how often it requires inpatient care. Patients who are at least 18 years old and have one of the conditions listed above are eligible to participate in the study.
18 years and older · First line · Phase IV
B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. A new mechanism of action (drug: BGB-16673) does not inhibit BTK but instead targets its destruction. The goal of the CaDAnCe-101 study is to investigate the optimal dosage, safety, and efficacy of the drug BGB-16673. Patients aged 18 and older with a variety of different NHLs are eligible to participate in the study. There must be no involvement of the central nervous system (CNS).
18 years and older · Relapsed / refractory · Phase I/II
B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a so-called Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. BTK inhibitors specifically target the metabolism of cancer cells and inhibit their growth. This study is investigating the optimal dosage, safety, and efficacy of a new BTK inhibitor called nemtabrutinib (MK-1026). Women and men aged 18 and older with certain types of NHL are eligible to participate in this study, including chronic lymphocytic leukemia (CLL/SLL), Richter syndrome, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström macroglobulinemia (WM).
18 years and older · Relapsed / refractory · Phase II
Acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (NHL) are malignant diseases of the blood and lymphatic system. CAR-T cells represent a new treatment option and are already approved for use in certain situations. This study investigates the safety, efficacy, and optimal dosage of MB-CART19.1, a new, as-yet-unapproved CAR-T cell therapy. Patients with CLL, ALL, or NHL can participate in this study starting at age 2.
1 years and older · Relapsed / refractory · Phase I/II
Acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are diseases of the blood and lymphatic system. A relatively new form of therapy is treatment with CAR-T cells, which has already been approved in some situations. There are various CAR-T cell therapies available. The goal of the HD-CAR-1 study is to investigate the appropriate dosage, safety, and efficacy of another new CAR-T cell therapy. Women and men aged 18 and older with ALL or NHL, as well as children aged 3 and older with ALL, are eligible to participate in this study if the disease has not responded adequately to prior treatments or has become active again.
3 years and older · Relapsed / refractory · Phase I/II
Chronic lymphocytic leukemia (CLL) is a malignant disease of the white blood cells. A number of standard treatments are available. However, as the disease progresses, it may become active again or fail to respond to treatment (relapse/refractory). Epcoritamab is a new bispecific antibody (medication) that is already approved for other conditions. The goal of the AETHER study is to investigate the efficacy, tolerability, and safety of the combination of epcoritamab and venetoclax (already approved). Eligible participants include women and men aged 18 and older with relapsed/refractory CLL or SLL (a variant of CLL) who have already received at least one systemic therapy.
18 years and older · Relapsed / refractory · Phase I/II
Chronic lymphocytic leukemia (CLL) and small-cell lymphocytic lymphoma (SLL) are slowly progressing cancers of the blood and the lymphatic system, respectively. Nowadays, an increasing number of drugs are being used that specifically target the signaling pathways of malignant cells, thereby destroying the tumor cells. This results in fewer side effects than with traditional chemotherapy drugs. The goal of the BRUIN-CLL-314 study is to compare the efficacy and safety of the specifically targeted BTK inhibitor pirtobrutinib with that of ibrutinib, the BTK inhibitor currently used as the standard of care. Eligible participants include women and men aged 18 and older who have chronic lymphocytic leukemia or small-cell lymphocytic lymphoma and who have either already received treatment or have not yet been treated.
18 years and older · First line · Phase III
B-cell non-Hodgkin lymphomas refer to a group of lymphomas in which a type of white blood cell undergoes malignant changes. Zilovertamab vedotin is an antibody-drug conjugate that has not yet been approved; it specifically targets cancer cells and is currently being evaluated in various clinical trials. The goal of the MK-2140-006 study is to evaluate the safety, tolerability, and efficacy of zilovertamab—both as a monotherapy and in combination with the new, as-yet-unapproved drug nemtabrutinib (a BTK inhibitor). Eligible participants include women and men aged 18 and older with one of the following B-cell lymphomas: mantle cell lymphoma (MCL), Richter syndrome, or follicular lymphoma (FL). Participants must have either failed to respond to prior treatment (refractory) or have experienced a recurrence of the disease.
18 years and older · Relapsed / refractory · Phase II
